TDC
PMD

Thompson Davis & Co’s Psychemedics Corporation PMD Stock Holding History

Thompson Davis & Co’s Portfolio PMD Stock Details PMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-500
Closed -$7K – 867
2013
Q4 		$7K Buy
+500
New +$6.88K 0.01% 524

Other funds holding PMD

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
TCM
Tieton Capital Management Yakima, Washington $299M AUM 54.55% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAIM
Punch & Associates Investment Management Edina, Minnesota $1.73B AUM 27.65% 1-Year Est. Return
DRZID
DePrince Race & Zollo Inc (DRZ) Winter Park, Florida $5.29B AUM 20.14% 1-Year Est. Return
KFA
Kelleher Financial Advisors New York $395M AUM 12.89% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NSIM
North Star Investment Management Chicago, Illinois $1.65B AUM 20.56% 1-Year Est. Return

Thompson Davis & Co's PMD Position: Q1 2014 in Review

Thompson Davis & Co sold out of Psychemedics Corporation (PMD) in Q1 2014, closing a stake of 500 shares — an estimated $7K sold.

Thompson Davis & Co first reported a position in PMD in Q4 2013 and held it in 1 quarter. The position peaked at $7K in Q4 2013. 35 funds tracked by Wall St. Rank hold PMD as of Q1 2014.

  • Thompson Davis & Co reported no remaining Psychemedics Corporation position as of Q1 2014 after selling out during the quarter.
  • Thompson Davis & Co sold 500 Psychemedics Corporation shares in Q1 2014, an estimated $7K.
  • Thompson Davis & Co first reported a position in Psychemedics Corporation in Q4 2013 and held it in 1 quarter.
  • Thompson Davis & Co's Psychemedics Corporation position peaked at $7K in Q4 2013.
  • 35 funds tracked by Wall St. Rank held Psychemedics Corporation as of Q1 2014.

Based on Thompson Davis & Co's 13F filing for Q1 2014, filed 9 May 2014.